COLL | Collegium Pharmaceutical, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	32.29 - 33.06
52 Week Range	28.39 - 42.29
Beta	0.77
Implied Volatility	55.89%
IV Rank	87.54%
Day's Volume	158,898
Average Volume	475,823
Shares Outstanding	32,250,200
Market Cap	1,045,551,484
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2015-05-07

Valuation
Profitability
Growth
Health
P/E Ratio	13.85
Forward P/E Ratio	N/A
EPS	2.34
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	197
Country	USA
Website	COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

COLL's peers: ALKS, AMPH, AMRX, ANIP, ASRT, PAHC, PROC, SSIC, EGRX, EOLS, PBH, RGC, PCRX, ITCI, RDY, DRRX, DVAX, EBS, ELAN, ESPR, EVO, HCM, INCR, IRWD, IXHL, KMDA, LNTH, NBIX, OPTN, ORGO, PRGO, RDHL, RMTI, SIGA, SUPN, TAK, TKNO, ALVO

*Chart delayed

Analyzing fundamentals for COLL we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is moderate, Growth is good and Health is frighteningly weak. For more detailed analysis please see COLL Fundamentals page.

Watching at COLL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on COLL Technicals page.